Centene announced that it has signed a definitive agreement to sell Apixio, an artificial intelligence platform that enables value-based care, to New Mountain Capital, a growth-oriented investment firm with more than $37B in assets under management. Centene acquired Apixio in December 2020. With a patented data science infrastructure, Apixio analyzes structured and unstructured data to develop high-fidelity patient health profiles and support value-based care programs. The transaction is subject to customary closing conditions, including regulatory approvals. The company expects the transaction to be neutral to 2023 adjusted EPS.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on CNC:
- CENTENE CORPORATION SIGNS DEFINITIVE AGREEMENT TO DIVEST APIXIO TO NEW MOUNTAIN CAPITAL
- Centene price target lowered to $87 from $95 at Stephens
- Centene price target lowered to $87 from $94 at Credit Suisse
- Centene price target lowered to $86 from $90 at Barclays
- Early notable gainers among liquid option names on April 25th
